




# DECISION

**DEcompensated CirrhoSIs:**  
**identification of new cOmBiNatorial therapies based**  
**on systems approaches**



project duration  
5 ½ years

grant amount  
6 million €

10 countries  
21 institutions



[www.decision-for-liver.eu](http://www.decision-for-liver.eu)

kick-off  
1st April 2020

follow us on Twitter  
@Decision4Liver

The objective of **DECISION** is to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) or death. This consortium will take advantage of already existing large and clinically well-characterised patient cohorts to develop reliable prognostic and response tests and combinatorial therapies tailored to the needs of individual patients to decrease the risk of short-term death.

- Pathophysiologic elucidation of acute decompensated cirrhosis at the systems level (genetics, epigenetics, transcriptomics, metabolomics, lipidomics, miR, and analysis of extracellular vesicles)
- Integration of existing clinical data and new multi-omics data from 2,200 patients with more than 8,600 measurements
- Development of new combinatorial therapies
- Optimization of therapies using existing and new animal models
- Development of novel and robust tests for prediction of outcome following traditional treatment versus response to new therapies
- Phase II clinical trial to test new combination therapies
- Creation of new guidelines for outcome prediction and personalized treatment of acute decompensated cirrhosis to prevent ACLF and death



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847949.



Keyvisual composing: © eranicle (liver) and Matjaz Slanic (light spots)